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Abstract
Objectives—To characterize uptake and correlates of effective contraceptive use postpartum.
Study Design—We analyzed data from a national, cross-sectional evaluation of prevention of 
mother-to-child HIV transmission programs that enrolled women attending 6-week or 9-month 
infant immunization visits at 120 Kenyan maternal and child health clinics. We classified women 
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who resumed sexual activity postpartum and did not desire a child within 2 years as having a need 
for family planning (FP).
Results—We included 955 (94%) of 1012 women 8–10 months postpartum in the analysis. Mean 
age was 25.8 years and 36% were primigravidas. By 9-months postpartum 62% of all women used 
contraception and 59% used effective contraception (injectables, implants, intrauterine devices 
[IUDs], oral contraceptives [OCs], and tubal ligations). Most contraceptive users (61%) used 
injectables, followed by implants (10%), OCs (6%), IUDs (4%), and condoms alone (2%). The 
majority (n=733, 77%) had a need for FP and 67% of 733 women with FP need used effective 
contraception. Among women with a need for FP, effective contraception use was higher among 
those who discussed FP in postnatal care (PNC) than who did not discuss FP in PNC (Prevalence 
Ratio (PR) for PNC alone: 1.35 (95% Confidence Interval [CI]:1.16-1.58; PR for PNC and 
antenatal care [ANC]:1.42, 95% CI: 1.21-1.67; p=0.001 for both).
Conclusions—Two-thirds of postpartum women with a need for FP used effective contraception 
at 9-months postpartum, and use was associated with discussing FP during PNC.
Implications—Integrating FP counseling in ANC/PNC could be an effective strategy to increase 
effective contraception use.
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1.0 INTRODUCTION
Reducing unmet need for family planning (FP) is a global public health priority, and a 
critical component of the post-2015 sustainable development goals (SDGs) and FP2020 
initiative.[1, 2] Postpartum women benefit from FP as a strategy to plan and space their 
births. Short interpregnancy intervals are associated with higher risk of infant mortality, 
preterm birth, low birthweight, and small-for-gestational-age.[3, 4] Using effective FP 
methods helps extend the interpregnancy interval to reduce these maternal and child health 
(MCH) risks. Yet, unmet need for FP during the postpartum period remains high. Data from 
women ≤2 years postpartum participating in Demographic and Health Surveys (DHS) in 
low- and bottom- income countries (LMIC) suggest unmet need exceeds 60% using a 
prospective definition of unmet need.[5] In Kenya, unmet need has declined among the 
general population between 2008 and 2014; however, more recent data on unmet need 
during the postpartum period are lacking.[6] In addition, method mix in Kenya has shifted 
during this same time period with higher use of implants, but temporal changes and 
correlates of specific FP methods have not been well characterized among postpartum 
Kenyan women.
Since over one-third of women in LMICs introduce complementary infant feeds before 6 
months postpartum, effectiveness of the lactational amenorrhea method (LAM) for 
pregnancy prevention is diminished.[7] Thus, it is essential for postpartum women to receive 
FP services and effective methods early to achieve healthy birth spacing and prevent 
unintended pregnancies. Previous studies report that women who attend more antenatal care 
(ANC) visits, deliver with a skilled birth attendant, or attend postnatal care (PNC) are more 
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likely to use postpartum contraception.[8–12] However, other factors may also impact use of 
FP during the postpartum period.
We characterized uptake and correlates of effective contraception, and specific types of FP, 
using data from a survey of postpartum women sampled from 120 facilities across Kenya.
2.0 MATERIAL AND METHODS
2.1 Study design and sampling
In 2013, we conducted a cross-sectional study in MCH clinics providing ANC and PNC 
throughout Kenya to assess coverage and uptake of prevention of mother-to-child HIV 
transmission (PMTCT) services as previously described.[13] Briefly, we used probability 
proportionate to size sampling to select 121 MCH clinics in seven of the eight geographical 
regions in Kenya from which all mother-infant pairs were sampled to participate during a 5-
day period per clinic. We classified facility size based on annual number of ANC clinic 
visits in 2011 and excluded “small” (<500 visits) and/or North Eastern Province facilities 
due to logistical constraints. (Figure 1).
2.2 Study procedures
Study nurses enrolled women attending routine 6-week or 9-month immunization visits and 
administered a survey on demographic and clinical characteristics, reproductive and medical 
history, and partner characteristics. We asked women whether they were trying to become 
pregnant or prevent pregnancy when they became pregnant, about their future fertility 
intentions, and about their current FP use. Women were also asked about whether anyone 
has talked to them about FP, and if yes, the timing and setting of the discussion (ANC, PNC, 
non-ANC/PNC, non-health care setting, family/community, or other setting). The Hurt/
Insult/Threaten/Scream (HITS) scale was used to determine history of intimate partner 
violence (IPV).[14]
Ethical review committees at the Kenya Medical Research Institute and the University of 
Washington, and the Associate Director for Science at the U.S. Centers for Disease Control 
and Prevention, approved all study procedures.
2.3 Contraceptive definitions and statistical analysis
Modern contraception included condoms, injectables, implants, intrauterine devices (IUDs), 
oral contraceptives (OCs), and tubal ligations (TL). Long-acting, reversible contraception 
(LARC) included IUDs and implants. Effective contraception included all modern 
contraceptives except condoms alone. [15–17]. Dual method use consisted of condoms plus 
another effective contraceptive method. We defined women with a need for FP as those who 
resumed sexual activity after delivery and did not desire a child within the next two years; 
women with an unmet need for FP were women with a need for FP who were not using 
modern contraception. We identified correlates of effective contraceptive use among women 
who had a need for FP using Chi-squared tests for proportions and T-tests for continuous 
measures and univariate Poisson generalized linear models with a log-link function, an 
approach used when the outcome prevalence is high.[18, 19] We applied survey weights and 
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clinic-level clustering adjustments to account for the sampling design and ensure 
representativeness; reported percentages are weighted. Variables significant at p<0.10 were 
included in a multivariate Poisson generalized linear model. We included the variable with 
the least amount of data missing in multivariate models if variables were collinear. Variables 
with p>0.05 were removed from the final multivariate model. We used Stata 13.1/MP svy 
commands (Stata Corporation, College Station, TX) to perform statistical analyses.
3.0 RESULTS
In total, 955 (94%) of 1012 women 8–10 months postpartum attending 9-month infant 
immunization visits were included in the analysis (Figure 2). Mean age was 25.8 years 
(standard deviation [SD] 5.8) and mean years of completed education was 9.0 (SD 3.7) 
(Table 1). Most (88%) women were married, with mean relationship duration of 5.7 years 
(SD 4.9) among women with current partners. Overall, HIV prevalence was 7%. Over one-
third (36%) of women were primigravidas and the mean number of living children was 2.4 
(SD 1.7). Only half of women had attended ≥4 ANC clinic visits and 69% delivered in a 
facility (Table 1).
Among all 955 postpartum women, most (94%) reported no desire for children within the 
next two years and 80% resumed sexual activity by 9-months postpartum. Overall, 59% of 
all postpartum women (n=955) reported using modern contraception; the most common 
method was injectable (38%) (Figure 3). LARC was used by 12% of postpartum women. 
Less than 1% of women used TL, non-modern methods, or dual methods. Over half (56%) 
of postpartum women used effective contraception; among these women 61% used 
injectables, followed by implants (17%), OCs (11%), and IUDs (7%). Uptake of effective 
contraception varied regionally: Central (71%), Nairobi (65%), Eastern (62%), Western 
(59%), Nyanza (57%), Coast (55%), and Rift Valley (52%). Overall, 77% (n=733) of 
postpartum women had a need for FP. Among postpartum women with a need for FP, 30% 
were not currently using modern contraception.
Uptake of modern contraception and effective contraception was slightly lower among all 
postpartum women (62% and 59%, respectively) than the subset in women with a need for 
FP (70% and 67%, respectively) (Figures 4a and b). Injectable and LARC use were both 
similar among all women and women a need for FP, respectively. Prevalence of effective 
contraceptive use was also similar among HIV-infected and HIV-uninfected women (Figure 
4a) (52% vs 60%, respectively; p=0.16).
3.1 FP discussion
Less than half (44%) of all postpartum women reported discussing FP with a provider during 
ANC or PNC. Among these women, 11% discussed FP in ANC alone, 17% in PNC alone, 
and 16% in both ANC and PNC. Women who used effective contraception were more likely 
than women who did not use effective contraception to have discussed FP with a provider in 
PNC alone (21% vs. 12%, respectively) or in both ANC and PNC (21% vs. 9%, 
respectfully) (p<0.001 for both).
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3.2 Correlates of effective contraceptive use
Among women with a need for FP, uptake of effective contraception was associated with 
higher education (Prevalence Ratio [PR] 1.06/year average increase, 95% Confidence 
Interval [CI] 1.03-1.08), household income ≥10,000 KSH/month (PR 1.21, 95% CI 
1.08-1.37), and having two living parents (PR 1.22, 95% CI 1.06-1.40) (Table 2). Women 
≤19 years were more likely to use effective contraception than older women. Effective 
contraceptive use was more common among women who delivered in a facility (PR 1.39, 
95% CI: 1.18-1.64), and discussed FP in a healthcare setting compared to women who did 
not have any discussion about FP or discussed FP outside of a healthcare setting. While 
discussing FP in ANC alone was not associated with effective contraceptive use, discussing 
FP in PNC alone (PR 1.35, 95% CI 1.16-1.58) or in combination with ANC (PR 1.42, 95% 
CI: 1.21-1.67) were both correlates of use. Effective contraception was not significantly 
associated with the number of current or lifetime sexual partners, history of IPV, 
breastfeeding duration, HIV status, or partner’s HIV status (p>0.10). Several factors 
remained significantly associated with effective contraceptive use in a multivariate model 
that included education, age category, both parents being alive, facility delivery, ≥ 2 living 
children, ≥ 4 ANC visits, and discussed FP with provider in ANC and/or PNC (Table 2). 
Effective contraception was associated with higher education (Adjusted Prevalence Ratio 
[APR] 1.04/year increase, 95% CI 1.02-1.06, p<0.001). Delivering in a facility (APR 1.23, 
95% CI 1.04-1.45, p=0.01) and discussing FP during PNC alone (APR 1.29, 95% CI 
1.20-1.51, p=0.002) or during both ANC and PNC (APR=1.40, 95% CI 1.21-1.63, p<0.001) 
were also associated with effective contraceptive use. We conducted exploratory analyses 
among all postpartum women (with and without a need for FP) to determine whether uptake 
of postpartum contraception varied by FP method type or HIV status, and whether correlates 
of injectable use (vs. no effective contraception) differed from overall effective contraceptive 
use. Correlates of effective contraceptive use were similar to the primary analysis, with the 
exception that male partner ANC attendance (APR=1.17, 95% CI 1.02-1.34, p=0.02), having 
both parents alive (APR=1.16, 95% CI 1.02-1.33, p=0.03), and age 20–34 years (APR 
compared to age ≥35 1.44, 95% CI 1.04-2.00, p=0.03) were also significant in the adjusted 
model. Similarly, results from the injectable specific analysis and analysis stratified by HIV 
status were similar to the primary findings (data not shown).
4.0 DISCUSSION
In this national survey of postpartum Kenyan women, we found that 56% were using 
effective contraception by 9-months postpartum, the majority (61%) of whom used 
injectable methods, and <1% used dual methods. The contraceptive prevalence rate (CPR) at 
9-months postpartum in our study was similar to other recent studies of Kenyan women; 
however, use of LARC and permanent methods was lower and injectable use was higher in 
our study.[6, 9] Overall, 34% of postpartum women had an unmet need for FP.
We found that women who discussed FP during PNC, alone or in combination with FP 
discussion in ANC, were more likely to use effective contraception. A recent review of 
interventions to improve postpartum contraception found that interventions delivered after, 
rather than before, delivery are generally more successful but results are mixed.[20] 
Achwoka et al. Page 5
Contraception. Author manuscript; available in PMC 2018 March 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Similarly, another observational study found no association between FP counseling in ANC 
and postpartum FP uptake.[21] Women in LMICs may be more receptive to FP discussions 
following delivery when there is a current or perceived future need for FP than during ANC.
[20, 22] In our study, more than half of women reported never discussing FP within a 
healthcare setting, despite routinely attending ANC and PNC visits. Current Kenyan national 
guidelines include providing FP counseling throughout the continuum of care in ANC, 
intrapartum, and at each PNC visit; and as integrated service provision within HIV care.[23] 
Since infant immunization coverage is high in sub-Saharan Africa, with frequent provider 
interactions during these visits, strategies to promote FP counseling in the early postpartum 
period during infant immunization visits could be a useful strategy to reduce unmet need 
during this period.
In our study, higher maternal education and utilization of MCH services (≥4 ANC visits and 
facility delivery) were significantly associated with contraceptive use, consistent with other 
studies.[8–12, 24] Postpartum FP use in LMICs has also been associated with urban 
residence,[8] being married,[12] greater wealth and education,[10–12] achievement of 
desired family size and current fertility desire.[24] In contrast to our study, a study 
conducted in five LMICs found that younger postpartum women (<20 years old) were 24% 
more likely than women ≥30 years to have an unmet need for FP.[9] Together, these factors 
may be markers of empowerment and access to information that facilitate uptake of 
postpartum FP.
Over one-third of postpartum women in our study used injectables, and use was similar by 
HIV status. In response to findings from some, but not all, studies showing an association 
between depot medroxyprogesterone acetate (DMPA) and increased risk of HIV acquisition, 
[25–27] WHO recommended expanding the contraceptive method mix to include the full 
range of contraceptive methods (particularly implants and IUDs). Due to injectable 
widespread use in many regions with high HIV incidence, it is important to weigh potential 
HIV-related risks with potential benefits to avert maternal deaths via injectables.[28] 
Increasing implant use among postpartum women may help alleviate these HIV-related risks, 
and maintain MCH benefits. Implants have many characteristics that make them particularly 
well-suited for postpartum women, including the ability to be inserted immediately 
postpartum, breastfeeding compatibility, longer-term coverage, high effectiveness, and no 
need for re-dosing.[29] However, LARC use has previously been reported to be low (<4%) 
among postpartum women in sub-Saharan Africa.[9] Our data suggest implants are 
increasingly an acceptable FP method for postpartum women, with 10% using selecting this 
method, similar to the general population.[6] Thus, implants may increasing represent a 
larger proportion of the method mix to postpartum women who are offered them.
Our study had several strengths. We included adolescents (age 14-17) and unmarried 
postpartum women sampled nationally, restricted most analyses to women with a need for 
FP, and excluded FP methods with high failure rates. The study also had some limitations. 
One province was not included; however, it is sparsely populated and the sampling frame 
excluded small facilities; we did not measure contraceptive discontinuations or switching, 
and results may not be generalizable to women who do not attend PNC. Finally, we had 
limited power to assess correlates of contraceptive use among HIV-infected women.
Achwoka et al. Page 6
Contraception. Author manuscript; available in PMC 2018 March 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Promoting FP during the postpartum period is a high-impact and cost-effective approach to 
improve MCH.[30] Strategies that better integrate patient-centered FP counseling and 
education within ANC and PNC as part of the routine package of MCH services, and 
provide comprehensive counseling to include methods with longer-term coverage could be 
effective approaches to meet postpartum FP needs. Further research to provide critical 
insights to enhance FP counseling approaches for postpartum women who are already 
accessible in the healthcare system, such as concerns about side effects and compatibility 
with breastfeeding, and data on method satisfaction and continuation rates among 
postpartum women, may help improve care.
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Figure 1. Study locations (n=120) and regional uptake of effective contraceptive methods among 
Kenyan postpartum women attending maternal and child health clinics, 2013
Percentages are weighted
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Figure 2. Study flowchart for Kenyan postpartum women attending maternal and child health 
clinics, 2013
*Not mutually exclusive. PMTCT=prevention of mother-to-child HIV transmission; 
MCH=maternal and child health Modern contraception included condoms, injectables, 
implants, intrauterine devices, oral contraceptives, and tubal ligations; effective 
contraception included all modern contraception except condoms. Women with unmet need 
reported resuming sexual activity after delivery and not desiring children within the next two 
years. Percentages are weighted.
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Figure 3. Contraceptive methods used among Kenyan postpartum women attending maternal 
and child health clinics, 2013
IUD= intrauterine device; OC = oral contraceptives; TL=tubal ligation. Dual methods 
include condoms and another effective method (injectables, implants, IUDs, OCs, and TL). 
Percentages are weighted. Percentages rounded up or down to nearest integer if >1%, which 
results in total exceeding 100%. Women with a need for FP had resumed sexual activity by 9 
months postpartum and did not desire more children in the next 2 years.
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Figure 4. Frequency of contraceptive use, by type and HIV status, among Kenyan postpartum 
women attending maternal and child health clinics, 2013
Women with unmet need reported resuming sexual activity after delivery and not desiring 
children within the next two years.
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